Enanta Pharma (ENTA) Tops Q1 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Enanta Pharmaceuticals (ENTA) PT Raised to $82 at Baird
February 8, 2018 6:43 AM ESTBaird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $82.00 (from $46.00) while maintaining a Neutral rating on strong Hep C royalties/pipeline progress.
... MoreJPMorgan Downgrades Enanta Pharmaceuticals (ENTA) to Neutral
February 8, 2018 4:40 AM ESTJPMorgan downgraded Enanta Pharmaceuticals (NASDAQ: ENTA) from Overweight to Neutral with a price target of $95.00 (from $55.00).
Analyst Jessica Fye steps to the sideline following the strong upside move noting the improvement in HCV royalties and lower tax rate in the US as... More
